Clinical Trial

Relacorilant in Combination With Nab-Paclitaxel in Advanced, Platinum-Resistant, High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian-Tube Cancer

Active, Not Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
The primary objectives of this study are to evaluate progression-free survival (PFS) by blinded independent central review (BICR) and overall survival (OS) (evaluated independently, as dual primary endpoints) in patients treated with intermittent regimen of Relacorilant in combination with nab-paclitaxel compared with patients treated with nab-paclitaxel monotherapy.
Protocol Amendment History 58 amendments
This ClinicalTrials.gov record has been amended 58 times since 2022-02-16; most recent amendment 2026-03-30.
Status change: Recruiting → Active, Not Recruiting 2024-04-08
Status change: Not Yet Recruiting → Recruiting 2022-07-13
Trial Details
NCT Number NCT05257408
Lead Sponsor Corcept Therapeutics
Collaborators: Gynecologic Oncology Group
Conditions Ovarian Neoplasm, Fallopian Tube Neoplasms, Peritoneal Neoplasms
Enrollment 381 participants
Start Date 2022-06-29
Primary Completion 2025-03-24 (estimated)
Study Completion 2026-03 (estimated)
Updated on ClinicalTrials.gov 2025-04-16